NPI: 1205859766 · BOONE, NC 28607 · Cardiovascular Disease Physician · NPI assigned 07/25/2006
Authorized official LONG, MARY controls 20+ related entities in our dataset. Read more
| Authorized Official | LONG, MARY (SR VP MEDICAL STAFF RELATIONS) |
| Parent Organization | APPALACHIAN REGIONAL HEALTHCARE SYSTEM |
| NPI Enumeration Date | 07/25/2006 |
Other providers sharing the same authorized official: LONG, MARY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,789 | $130K |
| 2019 | 9,440 | $117K |
| 2020 | 7,123 | $56K |
| 2021 | 9,338 | $118K |
| 2022 | 10,186 | $189K |
| 2023 | 9,394 | $258K |
| 2024 | 13,202 | $574K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 5,744 | 5,224 | $447K |
| 41899 | Unlisted procedure, dentoalveolar structures | 119 | 108 | $192K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 786 | 704 | $109K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6,840 | 5,212 | $82K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 13,177 | 9,379 | $72K |
| J3490 | Unclassified drugs | 2,807 | 1,386 | $67K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 401 | 344 | $61K |
| 80053 | Comprehensive metabolic panel | 9,994 | 6,887 | $58K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 950 | 864 | $49K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 38 | 38 | $34K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 31 | 27 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 837 | 748 | $21K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 103 | 89 | $17K |
| 36415 | Collection of venous blood by venipuncture | 10,136 | 7,618 | $15K |
| 83735 | 2,986 | 1,437 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 96 | 93 | $12K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 190 | 175 | $12K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 248 | 126 | $11K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 434 | 251 | $9K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 74 | 58 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 341 | 310 | $9K |
| 82728 | 925 | 798 | $8K | |
| 36591 | 515 | 250 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 65 | 64 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 49 | 41 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | 104 | 87 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 517 | 455 | $5K |
| 83550 | 900 | 775 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 247 | 200 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 17 | 17 | $5K |
| J2704 | Injection, propofol, 10 mg | 432 | 283 | $5K |
| 71045 | Radiologic examination, chest; single view | 147 | 136 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 261 | 216 | $4K |
| 83540 | 900 | 775 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 125 | 108 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 125 | 108 | $3K |
| 88342 | 55 | 55 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 301 | 249 | $2K |
| 81001 | 691 | 634 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 64 | 54 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | 12 | 12 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | 82 | 69 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | 406 | 276 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 29 | 27 | $2K |
| 86140 | 291 | 270 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 175 | 64 | $2K |
| 84484 | 167 | 142 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | 12 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 67 | 52 | $1K |
| 83690 | 170 | 154 | $1K | |
| 87634 | 13 | 12 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 29 | 24 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 13 | 12 | $1K |
| 80076 | 222 | 168 | $989.01 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 150 | 106 | $964.99 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15 | 12 | $938.94 |
| 85652 | 295 | 269 | $906.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 171 | 142 | $788.37 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 29 | 29 | $725.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 118 | 105 | $712.13 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 14 | 12 | $667.54 |
| 87486 | 17 | 17 | $592.91 | |
| 87581 | 17 | 17 | $592.91 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 17 | 17 | $592.91 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 24 | 24 | $491.87 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 31 | 27 | $482.70 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 54 | 38 | $429.37 |
| J7030 | Infusion, normal saline solution , 1000 cc | 43 | 40 | $429.04 |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 366 | 336 | $424.11 |
| 71046 | Radiologic examination, chest; 2 views | 12 | 12 | $390.01 |
| 86850 | 38 | 25 | $346.30 | |
| 83605 | 26 | 24 | $294.58 | |
| 88142 | 16 | 13 | $277.64 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 14 | 14 | $274.54 |
| 87641 | 23 | 13 | $255.56 | |
| 84703 | 26 | 24 | $239.49 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1,928 | 787 | $223.81 |
| 82947 | 49 | 38 | $172.17 | |
| 85379 | 13 | 13 | $131.89 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 98 | 95 | $123.41 |
| 85610 | 48 | 25 | $118.27 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 12 | 12 | $111.24 |
| 85730 | 26 | 13 | $73.62 | |
| 86592 | 13 | 13 | $63.72 | |
| 86901 | 38 | 25 | $60.25 | |
| 86900 | 38 | 25 | $60.25 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 17 | 14 | $57.87 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 14 | 13 | $45.04 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 17 | 12 | $39.92 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 144 | 126 | $20.46 |
| A9270 | Non-covered item or service | 29 | 13 | $0.00 |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 12 | 12 | $0.00 |